Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2015

01-03-2015 | Editorial

Bisphosphonates in the treatment of HIV-related osteoporosis

Authors: Fabio Vescini, Franco Grimaldi

Published in: Endocrine | Issue 2/2015

Login to get access

Excerpt

In this number, Pepe et al. are publishing a paper evaluating the effects of 1 year of risedronate treatment on bone mineral density (BMD) in HIV-infected patients with or without hypogonadism [1]. Their results show that also, risedronate is effective in the therapeutic management of osteoporosis in HIV, as well as alendronate and zoledronate. …
Literature
1.
J. Pepe, A.M. Isidori, M. Falciano, G. Iaiani, A. Salotti, D. Diacinti, R. Del Fiacco, E. Sbardella, C. Cipriani, S. Piemonte, O. Raimo, P. Biondi, F. Biamonte, A. Lenzi, S. Minisola, Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study. Endocrine (2014). doi:10.​1007/​s12020-014-0349-0
2.
M. Borderi, L. Calza, V. Colangeli, E. Vanino, P. Viale, D. Gibellini, M.C. Re, Prevalence of subclinical vertebral fractures in HIV-infected patients. New Microbiol. 37, 25–32 (2014)PubMed
3.
C. Torti, G. Mazziotti, P.A. Soldini, E. Focà, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)CrossRefPubMed
4.
J.D. Lundgren, M. Battegay, G. Behrens, S. De Wit, G. Guaraldi, C. Katlama, E. Martinez, D. Nair, W.G. Powderly, P. Reiss, J. Sutinen, A. Vigano, EACS Executive Committee, European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 9(2), 72–81 (2008)CrossRefPubMed
5.
G.A. McComsey, P. Tebas, E. Shane, M.T. Yin, E.T. Overton, J.S. Huang, G.M. Aldrovandi, S.W. Cardoso, J.L. Santana, T.T. Brown, Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin. Infect. Dis. 51(8), 937–946 (2010)CrossRefPubMedCentralPubMed
6.
G. Guaraldi, G. Orlando, G. Madeddu, F. Vescini, P. Ventura, S. Campostrini, M.S. Mura, N. Parise, R. Caudarella, R. Esposito, Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin. Trials 5(5), 269–277 (2004)CrossRefPubMed
7.
K. Mondy, W.G. Powderly, S.A. Claxton, K.H. Yarasheski, M. Royal, J.S. Stoneman, M.E. Hoffmann, P. Tebas, Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J. Acquir. Immune. Defic. Syndr. 38(4), 426–431 (2005)CrossRefPubMed
8.
G.A. McComsey, M.A. Kendall, P. Tebas, S. Swindells, E. Hogg, B. Alston-Smith, C. Suckow, G. Gopalakrishnan, C. Benson, D.A. Wohl, Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 21(18), 2473–2482 (2007)CrossRefPubMed
9.
M.J. Bolland, A.B. Grey, A.M. Horne, S.E. Briggs, M.G. Thomas, R.B. Ellis-Pegler, A.F. Woodhouse, G.D. Gamble, I.R. Reid, Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J. Clin. Endocrinol. Metab. 92(4), 1283–1288 (2007)CrossRefPubMed
10.
M.J. Bolland, A. Grey, A.M. Horne, S.E. Briggs, M.G. Thomas, R.B. Ellis-Pegler, G.D. Gamble, I.R. Reid, Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J. Clin. Endocrinol. Metab. 97(6), 1922–1928 (2012)CrossRefPubMed
11.
F. Vescini, A. Cozzi-Lepri, M. Borderi, M.C. Re, F. Maggiolo, A. De Luca, G. Cassola, V. Vullo, G. Carosi, A. Antinori, V. Tozzi, A.D. Monforte, Icona Foundation Study Group, Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J. Acquir. Immune. Defic. Syndr. 58, 163–172 (2011)CrossRefPubMed
12.
S. Adami, S. Giannini, G. Bianchi, L. Sinigaglia, O. Di Munno, C.E. Fiore, S. Minisola, M. Rossini, Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos. Int. 20, 239–244 (2009)CrossRefPubMed
13.
M.L. Gourlay, J.P. Fine, J.S. Preisser, R.C. May, C. Li, L.Y. Lui, D.F. Ransohoff, J.A. Cauley, K.E. Ensrud, Study of Osteoporotic Fractures Research Group, Bone-density testing interval and transition to osteoporosis in older women. N. Engl. J. Med. 366, 225–233 (2012)CrossRefPubMedCentralPubMed
14.
15.
G. Campisi, L.L. Russo, A. Agrillo, P. Vescovi, V. Fusco, A. Bedogni, BRONJ expert panel recommendation of the Italian Societies for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on Bisphosphonate-Related Osteonecrosis of the Jaws: risk assessment, preventive strategies and dental management. Ital. J. Maxillofac. Surg. 22(2), 103–124 (2011)
Metadata
Title
Bisphosphonates in the treatment of HIV-related osteoporosis
Authors
Fabio Vescini
Franco Grimaldi
Publication date
01-03-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0488-3

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue

Original Article

Involvement of RBP4 in hyperinsulinism-induced vascular smooth muscle cell proliferation

Original Article

Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients

Erratum

Erratum to: Metformin in women with PCOS, Pros

Viewpoint

Remission of type 2 diabetes: is bariatric surgery ready for prime time?

Original Article

Comparative analysis of vaspin in pregnant women with and without gestational diabetes mellitus and healthy non-pregnant women

Meta-Analysis

Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits